Crohn’s disease (CD) is a chronic inflammatory disorder of the gastrointestinal tract characterized by diarrhea, abdominal pain, and weight loss. Children with CD have a more-complicated disease course compared with adult patients. The primary goal of pediatric CD treatment is to induce and maintain remission as quickly as possible. Historically, treatment of pediatric CD would begin with safe, albeit often less-efficacious, conventional agents (e.g., 5-ASAs) and then progress to more-potent drugs, such as biologics and/or immunosuppressants. However, this scenario has largely changed, and physicians increasingly initiate treatment with TNF-alpha inhibitors (e.g., Janssen/Merck’s Remicade, AbbVie/Eisai’s Humira). The non-TNF biologics, including Takeda’s Entyvio and Janssen’s Stelara, also have a growing market share.
Real World data
Longitudinal patient-level claims data analysis
Key Drugs Covered
Humira, Remicade, Entyvio, Stelara, Cimzia, aminosalicylates, immunosuppressants
Key Analysis provided
Treatment Algorithms: Claims Data Analysis provides detailed analysis of brand use across different lines of therapy using real-world patient-level claims data so that clients can accurately assess their source of business and quantify areas of opportunity for increasing their brand share.